Grants (medicine, biopharmaceutical research | worldwide)

Alnylam Pharmaceuticals

The Grants from the biopharmaceutical company Alnylam support organizations worldwide in projects that enable the advancement of patient care, focusing on Transthyretin-mediated Amyloidosis, Acute Hepatic Porphyria, and Primary Hyperoxaluria Type 1. Alnylam supports unsolicited requests for Continuing Medical Education Grants (CME), Educational Grants (non-CME), and Fellowships. Applications may be submitted at any time, but must be sent at least 45 days prior to the activity start date.

Key contacts

• Tiffany Patrick

  Head of Global Patient Advocacy and Engagement

  [email protected]